Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Nadia Haj Mohammad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4688-2921; OpenAlex author ID A5086553242. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 4 papers · 2021: 6 papers · 2022: 3 papers · 2023: 2 papers · 2024: 5 papers · 2025: 1 paper · 2026: 2 papers

Papers 30

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real-World Population. Co-author DOI 10.1002/jso.70391↗
  3. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  4. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  5. 31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data. Co-author DOI 10.1002/jmri.29326↗
  6. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  7. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  8. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  9. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Co-author DOI 10.1002/ijc.34276↗
  10. Correction: A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation … Co-author DOI 10.1186/s13063-022-07036-8↗
  11. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.09.004↗
  12. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Co-author DOI 10.1097/sla.0000000000004093↗
  13. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARC… Co-author DOI 10.1186/s13063-022-06829-1↗
  14. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… Co-author DOI 10.1002/jso.26567↗
  15. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  16. The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. Co-author DOI 10.1016/j.pan.2020.11.012↗
  17. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Co-author DOI 10.1080/1354750x.2021.1893814↗
  18. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  19. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. Co-author DOI 10.6004/jnccn.2021.7028↗
  20. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2019.11.002↗
  21. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. Co-author DOI 10.1016/j.hpb.2019.06.019↗
  22. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Co-author DOI 10.1080/0284186x.2020.1725241↗
  23. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  24. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. Co-author DOI 10.1016/j.ejca.2018.10.008↗
  25. Postoperative surveillance of pancreatic cancer patients. Co-author DOI 10.1016/j.ejso.2019.05.031↗
  26. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a pro… Co-author DOI 10.1016/j.hpb.2019.02.017↗
  27. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. First author DOI 10.1002/cam4.1240↗
  28. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. Co-author DOI 10.1007/s00432-016-2140-5↗
  29. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5373-2↗
  30. Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. First author DOI 10.3109/0284186x.2014.953257↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Izaak Quintus Molenaar · 21 shared papers, 2016–2026 · strength 2.59
  2. Marc G. Besselink · 24 shared papers, 2016–2025 · strength 2.55
  3. Hjalmar C. van Santvoort · 19 shared papers, 2016–2026 · strength 2.36
  4. Johanna W. Wilmink · 20 shared papers, 2016–2025 · strength 2.10
  5. Hanneke W.M. van Laarhoven · 17 shared papers, 2015–2025 · strength 1.83
  6. Ignace H. J. T. de Hingh · 16 shared papers, 2015–2025 · strength 1.69
  7. Vincent Erwin de Meijer · 12 shared papers, 2020–2025 · strength 1.36
  8. Martijn W.J. Stommel · 12 shared papers, 2019–2025 · strength 1.35
  9. Lois A. Daamen · 9 shared papers, 2019–2026 · strength 1.27
  10. Bas Groot Koerkamp · 9 shared papers, 2019–2025 · strength 1.06
  11. Judith de Vos‐Geelen · 9 shared papers, 2020–2025 · strength 0.94
  12. Martijn Intven · 7 shared papers, 2019–2024 · strength 0.86
  13. Robert C. Verdonk · 5 shared papers, 2022–2026 · strength 0.83
  14. Casper H.J. van Eijck · 6 shared papers, 2020–2025 · strength 0.73
  15. Sebastiaan Festen · 7 shared papers, 2021–2024 · strength 0.71
  16. Gert J. Meijer · 5 shared papers, 2022–2024 · strength 0.67
  17. Geertjan van Tienhoven · 5 shared papers, 2020–2024 · strength 0.65
  18. Marieke S. Walma · 7 shared papers, 2016–2024 · strength 0.63
  19. Lilly J. H. Brada · 6 shared papers, 2021–2024 · strength 0.60
  20. Vincent P. Groot · 5 shared papers, 2019–2024 · strength 0.60
  21. Lydia G. van der Geest · 6 shared papers, 2017–2021 · strength 0.60
  22. Marjolein Y.V. Homs · 5 shared papers, 2020–2025 · strength 0.59
  23. Hanne D. Heerkens · 4 shared papers, 2022–2024 · strength 0.56
  24. Iris W.J.M. van Goor · 4 shared papers, 2022–2024 · strength 0.56
  25. Leonard W. F. Seelen · 3 shared papers, 2024–2025 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.